SG11201901438VA - Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate - Google Patents

Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Info

Publication number
SG11201901438VA
SG11201901438VA SG11201901438VA SG11201901438VA SG11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA
Authority
SG
Singapore
Prior art keywords
international
solid forms
cenicriviroc mesylate
pct
cambridge
Prior art date
Application number
SG11201901438VA
Inventor
Pasit Phiasivongsa
Martin Ian Cooper
Emma Kay SHARP
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of SG11201901438VA publication Critical patent/SG11201901438VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIP0 I PCT ill~~~~~~~~ 011101010VIIIOH olo olommoonmll °nom oimIE (10) International Publication Number WO 2018/045043 Al (51) International Patent Classification: A61K 31/395 (2006.01) A61K 31/513 (2006.01) A61K 31/4164 (2006.01) A61K 31/55 (2006.01) A61K 31/4178 (2006.01) A61K 45/00 (2006.01) (21) International Application Number: PCT/US2017/049400 (22) International Filing Date: 30 August 2017 (30.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/382,153 31 August 2016 (31.08.2016) US (71) Applicant: TOBIRA THERAPEUTICS, INC. [US/US]; 400 Interpace Parkway, Parsippany, New Jersey 07054 (US). (72) Inventors: PHIASIVONGSA, Pasit; 930 Mission Road, Unit 29, South San Francisco, California 94080 (US). COOPER, Martin Ian; c/o Johnson Matthey Plc., Phar- morphix, 250 Cambridge Science Park, Milton Road, Cam- bridge Cambridgeshire CB4 OWE (GB). SHARP, Em- ma Kay; c/o Johnson Matthey Plc., Pharmorphix, 250 Cambridge Science Park, Milton Road, Cambridge Cam- bridgeshire CB4 OWE (GB). (74) Agent: BLINKA, Thomas A. et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, Dis- trict of Columbia 20004-2400 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE 24 2-Theta Scale FIG. 1 (57) : The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions C thereof and methods of their use. [Continued on next page] WO 2018/045043 Al MIDEDIMOHNIIMEIHRIMENNIMIRMOVOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201901438VA 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate SG11201901438VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
SG11201901438VA true SG11201901438VA (en) 2019-03-28

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901438VA SG11201901438VA (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Country Status (13)

Country Link
US (1) US10301287B2 (en)
EP (1) EP3506896A4 (en)
JP (2) JP2019526628A (en)
KR (1) KR20190057066A (en)
CN (1) CN110167550A (en)
AU (1) AU2017321594A1 (en)
BR (1) BR112019003987A2 (en)
CA (1) CA3034606A1 (en)
MX (1) MX2019002057A (en)
RU (1) RU2019109019A (en)
SG (1) SG11201901438VA (en)
TW (1) TW201823235A (en)
WO (1) WO2018045043A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (en) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 Acrylamide compound crystal form and preparation method therefor
WO2019245518A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245534A1 (en) * 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11426931B2 (en) 2018-06-19 2022-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional printing
EP3844209B1 (en) * 2018-08-31 2022-06-22 Evonik Operations GmbH Process for preparing a polymer powder
WO2021133811A1 (en) * 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
JP7374372B2 (en) 2021-02-22 2023-11-06 旭化成株式会社 Composition containing cellulose nanofibers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (en) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk Novel imidazole derivative and antiulcer agent containing said derivative as active component
ATE199721T1 (en) 1994-07-04 2001-03-15 Takeda Chemical Industries Ltd PHOSPHONIC ACID COMPOUNDS IN PRODUCTION AND USE
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
CA2337307A1 (en) 1998-08-20 2000-03-02 Osamu Nishimura Quaternary ammonium salts and their use
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
US7371772B2 (en) * 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
KR20040091127A (en) 2002-03-12 2004-10-27 다케다 야쿠힌 고교 가부시키가이샤 Process for producing optically active sulfoxide derivative
WO2005089714A1 (en) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion stabilizer
JP2007269628A (en) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd Crystal of pharmaceutical compound
GT200600148A (en) 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
MX350974B (en) 2010-11-18 2017-09-27 Univ Yale Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus.
JP2015520144A (en) * 2012-05-11 2015-07-16 アクロン・モレキュールズ・アクチェンゲゼルシャフトＡｋｒｏｎ Ｍｏｌｅｃｕｌｅｓ Ａｇ Use of compounds for the treatment of pain
MY180145A (en) 2013-05-15 2020-11-23 Tobira Therapeutics Inc Cenicriviroc compositions and methods of making and using the same
KR20160132489A (en) 2014-03-21 2016-11-18 토비라 쎄라퓨틱스, 인크. Cenicriviroc for the treatment of fibrosis
EP3148538A4 (en) * 2014-06-02 2018-01-17 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
MX2017008280A (en) * 2014-12-23 2017-12-07 Tobira Therapeutics Inc Process of making cenicriviroc and related analogs.

Also Published As

Publication number Publication date
US10301287B2 (en) 2019-05-28
MX2019002057A (en) 2019-11-18
AU2017321594A1 (en) 2019-04-18
WO2018045043A1 (en) 2018-03-08
JP2022137223A (en) 2022-09-21
TW201823235A (en) 2018-07-01
RU2019109019A (en) 2020-10-01
KR20190057066A (en) 2019-05-27
US20180057481A1 (en) 2018-03-01
RU2019109019A3 (en) 2021-08-23
BR112019003987A2 (en) 2019-05-28
EP3506896A4 (en) 2020-08-26
EP3506896A1 (en) 2019-07-10
JP2019526628A (en) 2019-09-19
CN110167550A (en) 2019-08-23
CA3034606A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201909949XA (en) Targeted immunotolerance
SG11201808990QA (en) Compositions for topical application of compounds
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201907023UA (en) Method of reducing neutropenia
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201805072PA (en) Nicotine powder delivery system
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809594WA (en) Nicotine particles and compositions
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201805204WA (en) Nicotine particle capsule
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201408171SA (en) Fbxo3 inhibitors
SG11201806623VA (en) Bacteria over-expressing c-di-amp and therapeutic methods